Skip to primary navigation
Skip to main content
Skip to footer

Exopharm

Home
Partnering
Investors
About Us
Press and Resource Centre
- Articles
- Understanding Exosomes

Exopharm Ltd — Refreshing Medicine, Today

Exopharm's mission is to be the global leader in exosome-based medicines.

Exopharm is an Australian regenerative medicine biopharmaceutical company that is seeking to develop and commercialise exosomes as therapeutic agents – initially a product called Plexaris™ and later a product called Cevaris™.

As key messengers within the human body, exosomes exert powerful effects on the actions and behaviours of existing cells. Recent research shows that exosomes are potent, broad-acting, and play essential roles in cellular activity, particularly tissue remodeling, inflammatory regulation and immuno-modulation, that affect the body's ability to repair itself.

Despite promise of administering exosomes as a cell-free treatment, the therapeutic exosome market has been held back by one key technological challenge: an efficient exosome extraction and purification process technology that would enable the manufacture of exosome-based medicines at clinical and then pharmaceutical grade and scale.

Exopharm's LEAP Technology provides a key step in the downstream manufacturing process to isolate and purify exosomes from a variety of cell sources, including platelets and adult stem cells. LEAP technology has provided access to high-purity exosomes that launched a virtuous circle of innovation at Exopharm, allowing it to solve other manufacturing and characterization challenges and to bring an exosome-based medicine into human clinical trials for the first time.